Literature DB >> 7491134

Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States.

E M Lackritz1, G A Satten, J Aberle-Grasse, R Y Dodd, V P Raimondi, R S Janssen, W F Lewis, E P Notari, L R Petersen.   

Abstract

BACKGROUND: In the United States, transmission of the human immunodeficiency virus (HIV) by blood transfusion occurs almost exclusively when a recently infected blood donor is infectious but before antibodies to HIV become detectable (during the "window period"). We estimated the risk of HIV transmission caused by transfusion on the basis of the window period associated with the use of current, sensitive enzyme immunosorbent assays and recent data on HIV incidence among blood donors.
METHODS: We analyzed demographic and laboratory data on more than 4.1 million blood donations obtained in 1992 and 1993 in 19 regions served by the American National Red Cross, as well as the results of HIV-antibody tests of 4.9 million donations obtained in an additional 23 regions.
RESULTS: We estimated that, in the 19 study regions, 1 donation in every 360,000 (95 percent confidence interval, 210,000 to 1,140,000) was made during the window period. In addition, it is estimated that 1 in 2,600,000 donations was HIV-seropositive but was not identified as such because of an error in the laboratory. We estimated that 15 to 42 percent of window-period donations were discarded because they were seropositive on laboratory tests other than the HIV-antibody test. When these results were extrapolated to include the additional 23 Red Cross service regions, there was a risk of one case of HIV transmission for every 450,000 to 660,000 donations of screened blood. If the Red Cross centers are assumed to be representative of all U.S. blood centers, among the 12 million donations collected nationally each year an estimated 18 to 27 infectious donations are available for transfusion.
CONCLUSIONS: The estimated risk of transmitting HIV by the transfusion of screened blood is very small and nearly half that estimated previously, primarily because the sensitivity of enzyme immunosorbent assays has been improved.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491134     DOI: 10.1056/NEJM199512283332601

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  30 in total

1.  Are our donors safe?

Authors:  C Viswanathan
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

2.  Risk of HIV infection from blood transfusion in Montreal.

Authors:  R S Remis; G Delage; R W Palmer
Journal:  CMAJ       Date:  1997-08-15       Impact factor: 8.262

Review 3.  Technology and effect: HIV/AIDS testing in Brazil.

Authors:  J Biehl; D Coutinho; A L Outeiro
Journal:  Cult Med Psychiatry       Date:  2001-03

4.  The Changing Epidemic of HIV.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

5.  Performance of a multiplex qualitative PCR LCx assay for detection of human immunodeficiency virus type 1 (HIV-1) group M subtypes, group O, and HIV-2.

Authors:  K Abravaya; C Esping; R Hoenle; J Gorzowski; R Perry; P Kroeger; J Robinson; R Flanders
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 6.  Safety of the blood supply in Latin America.

Authors:  Gabriel A Schmunis; Jose R Cruz
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  The promised land of human immunology.

Authors:  Laura F Su; Arnold Han; Helen M McGuire; David Furman; Evan W Newell; Mark M Davis
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2014-03-17

8.  Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey.

Authors:  Claudio Velati; Luisa Romanò; Vanessa Piccinini; Giuseppe Marano; Liviana Catalano; Simonetta Pupella; Giuseppina Facco; Ilaria Pati; Maria Elena Tosti; Stefania Vaglio; Giuliano Grazzini; Alessandro Zanetti; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2018-06-26       Impact factor: 3.443

9.  Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines.

Authors:  Wendy Landier; Saro H Armenian; Jin Lee; Ola Thomas; F Lennie Wong; Liton Francisco; Claudia Herrera; Clare Kasper; Karla D Wilson; Meghan Zomorodi; Smita Bhatia
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

10.  Evidence-based guidelines for universal counselling and offering of HIV testing in pregnancy in Canada.

Authors:  L Samson; S King
Journal:  CMAJ       Date:  1998-06-02       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.